Vitamin D supplementation in systemic lupus erythematosus: relationship to disease activity, fatigue and the interferon signature gene expression

Table 2 Results obtained when the continuous variables at 6 and 12 months are compared with those at baseline

Variable	Time	Mean	SD	p value
SLEDAI-2K	Baseline	3.55	2.998
	6 months	3.06	2.707	0.324*
	12 months	2.45	2.158	0.028*
Clinical SLEDAI-2K	Baseline	1.97	2.614
	6 months	1.39	2.076	0.258*
	12 months	0.90	1.620	0.024*
FSS	Baseline	4.10	1.514
	6 months	3.95	1.623	0.465
	12 months	3.70	1.852	0.071
VAS pain	Baseline	3.74	2.966
	6 months	3.97	3.027	0.603
	12 months	3.35	3.115	0.276
HADS-D	Baseline	4.81	3.674
	6 months	5.55	3.767	0.084
	12 months	4.48	4.186	0.389
HADS-A	Baseline	8.58	4.703
	6 months	8.26	4.389	0.499
	12 months	8.29	4.776	0.605
PSQI	Baseline	6.66	4.218
	6 months	6.52	4.396	0.943
	12 months	6.16	4.352	0.289
mHAQ	Baseline	0.23	0.357
	6 months	0.29	0.402	0.146*
	12 months	0.28	0.444	0.111*
Corrected calcium (2.05–2.60 mmol/l)	Baseline	2.30	0.092
	6 months	2.28	0.085	0.139
	12 months	2.29	0.092	0.647
25-hydroxyvitamin D (30–100 ng/mL)	Baseline	21.74	6.444
	6 months	32.61	6.396	< 0.001
	12 months	28.32	8.368	0.001
Anti-dsDNA level (0.0–100 IU/mL)	Baseline	172.26	184.217
	6 months	154.99	151.173	0.032*
	12 months	154.11	153.276	0.045*
Prednisolone daily dose (mg)	Baseline	1.403	2.850
	6 months	1.550	2.973	0.144*
	12 months	0.937	2.459	0.068*

The p values have been obtained using the Paired samples t test for normally distributed variables and the Wilcoxon signed ranks test for non-normally distributed variables (as denoted by *). Statistically significant results are highlighted in bold

ISSN: 2520-1026